ArticleBJUI compass2026
Retroperitoneal lymph-node dissection for isolated nodal recurrence of renal cell carcinoma after nephrectomy: Contemporary outcomes of a case series.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Isolated retroperitoneal lymph-node (RPLN) recurrence after radical nephrectomy (RN) for renal cell carcinoma (RCC) is uncommon, and optimal management remains undefined. This study reports contemporary outcomes of retroperitoneal lymph-node dissection (RPLND) for isolated nodal recurrence, including in patients previously treated with stereotactic ablative body radiotherapy (SABR) or systemic therapy. Methods: A retrospective review was performed of all patients undergoing RPLND for isolated nodal recurrence of RCC between July 2023 and October 2024. Clinical, operative, and pathologic variables were collected, and postoperative complications were graded using the Clavien-Dindo system. Recurrence-free survival (RFS) was calculated from RPLND to recurrence or last follow-up. Results: Eight patients met inclusion criteria. Median age at RPLND was 59.5 years, and six were male. The median interval from RN to RPLND was 29 months. Median operative time was 255 min, estimated blood loss 300 mL, and hospital stay 6.5 days. One patient experienced postoperative complication (Clavien-Dindo IIIa). All specimens confirmed malignancy with negative margins. After a median follow-up of 18 months, three patients (37.5%) recurred, with a mean RFS of 15.3 months. Conclusions: RPLND is a safe and viable option for isolated nodal recurrence of RCC, offering complete resection and oncologic outcomes comparable to historical data, and may serve as an important component of multimodal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.